PE20030557A1 - Formulacion de dosificacion oral de fusion instantanea - Google Patents

Formulacion de dosificacion oral de fusion instantanea

Info

Publication number
PE20030557A1
PE20030557A1 PE2002000995A PE2002000995A PE20030557A1 PE 20030557 A1 PE20030557 A1 PE 20030557A1 PE 2002000995 A PE2002000995 A PE 2002000995A PE 2002000995 A PE2002000995 A PE 2002000995A PE 20030557 A1 PE20030557 A1 PE 20030557A1
Authority
PE
Peru
Prior art keywords
oral dosage
dosage formulation
calcium silicate
instant fusion
density
Prior art date
Application number
PE2002000995A
Other languages
English (en)
Inventor
Sanjeev H Kothari
Divyakant S Desai
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/973,226 external-priority patent/US20020076437A1/en
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of PE20030557A1 publication Critical patent/PE20030557A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Inorganic Chemistry (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

QUE COMPRENDE: a)UN MEDICAMENTO, TAL COMO ARIPIPRAZOL, ENTECAVIR, CEFPROZIL, PRAVASTATINA, CAPTOPRIL, GATIFLOXACINA, DESQUINOLONA, ENTRE OTROS; b)UN SUPERDESINTEGRANTE, TAL COMO LA CROSPOVIDONA; c)UN AGENTE DE DISPERSION, TAL COMO SILICATO DE CALCIO, TRISILICATO DE MAGNESIO O ACIDO SALICILICO; d)UN AGLUTINADOR; Y, e)UN AGENTE DE DISTRIBUCION, SELECCIONADO DE: SILICE AMORFO, TIERRA DIATOMACEA, TALCO, CAOLIN, ENTRE OTROS. DONDE, EL SILICATO DE CALCIO ES CRISTALINO CON UN AREA SUPERFICIAL APROXIMADA DE 90,4 m²/g, DENSIDAD VOLUMETRICA DE 0,094 g/cm³, UNA DENSIDAD REAL DE 2,596 g/cm³ Y UN CONTENIDO DE VOLATILES MENOR A 1% p/p. DICHA FORMULACION ORAL QUE SE DESINTEGRA FACILMENTE, ADEMAS ES ESTABLE Y PUEDE SER PREPARADA SIN LA AYUDA DE SOLVENTES Y LA NECESIDAD DE UNA MANIPULACION O MEDIO AMBIENTE ESPECIAL
PE2002000995A 2001-10-09 2002-10-09 Formulacion de dosificacion oral de fusion instantanea PE20030557A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US09/973,226 US20020076437A1 (en) 2000-04-12 2001-10-09 Flashmelt oral dosage formulation

Publications (1)

Publication Number Publication Date
PE20030557A1 true PE20030557A1 (es) 2003-06-22

Family

ID=38812694

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2002000995A PE20030557A1 (es) 2001-10-09 2002-10-09 Formulacion de dosificacion oral de fusion instantanea

Country Status (6)

Country Link
US (2) US20050019398A1 (es)
AR (2) AR036658A1 (es)
MY (1) MY127350A (es)
PE (1) PE20030557A1 (es)
TW (1) TWI324074B (es)
UY (1) UY27474A1 (es)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2311734C (en) * 2000-04-12 2011-03-08 Bristol-Myers Squibb Company Flash-melt oral dosage formulation
US6984377B2 (en) * 2002-05-29 2006-01-10 J. M. Huber Corporation Oral care products comprising calcium metasilicates
WO2007081367A1 (en) * 2006-01-05 2007-07-19 Teva Pharmaceutical Industries Ltd. Dry formulations of aripiprazole
BRPI0706280A2 (pt) * 2006-01-05 2011-03-22 Lifecycle Pharma As produto de comprimido carregável desintegrante, e, método para a preparação de um comprimido carregável desintegrante
CA2627693A1 (en) * 2006-01-05 2007-07-19 Teva Pharmaceutical Industries Ltd. Wet granulation pharmaceutical compositions of aripiprazole
PT1806130E (pt) * 2006-01-09 2010-05-11 Krka D D Novo Mesto Composições farmacêuticas sólidas que compreendem irbesartan
US9265732B2 (en) 2006-03-06 2016-02-23 Pozen Inc. Dosage forms for administering combinations of drugs
JP5535616B2 (ja) * 2006-03-31 2014-07-02 ルビコン リサーチ プライベート リミテッド 口腔内崩壊錠剤のための直接圧縮性複合材
TR200604349A2 (tr) 2006-08-15 2008-03-21 NOBEL İLAÇ SANAYii VE TiCARET A.Ş. Aripiprazol içeren farmasötik bileşimler
US20100092564A1 (en) * 2006-12-21 2010-04-15 Jae Han Park Composition of and Method for Preparing Orally Disintegrating Tablets
CA2673228A1 (en) * 2006-12-22 2008-07-03 Schering Corporation Disintegration promoters in solid dose wet granulation formulations
EP2155159B1 (en) * 2007-05-08 2019-07-10 Hercules LLC Robust rapid disintegration tablet formulation
EP2338474A1 (de) * 2009-12-23 2011-06-29 Ratiopharm GmbH Oral dispersible Tablette enthaltend kompaktierte Sildenafil-Base
US9316580B2 (en) 2011-03-21 2016-04-19 Coloright Ltd. Systems for custom coloration
MX2013010616A (es) * 2011-03-21 2014-08-18 Coloright Ltd Sistema de coloracion confeccionados.
WO2014104989A1 (en) * 2011-12-27 2014-07-03 Mahmut Bilgic Pharmaceutical compositions comprising aripiprazole
WO2013100878A1 (en) * 2011-12-27 2013-07-04 Mahmut Bilgic Pharmaceutical formulations comprising aripiprazole
CN107148560A (zh) 2013-09-26 2017-09-08 卡拉莱特有限公司 毛发阅读器、分配装置与相关的系统与方法
WO2015044394A1 (en) * 2013-09-30 2015-04-02 Sandoz Ag Pharmaceutical composition comprising low dose active pharmaceutical ingredient and preparation thereof
KR101925700B1 (ko) 2014-04-27 2018-12-05 콜로라이트 리미티드 맞춤형 모발-염색을 위한 장치 및 방법
WO2015166340A2 (en) 2014-04-27 2015-11-05 Coloright Ltd. Apparatus and method for analyzing hair and/or predicting an outcome of a hair-coloring treatment
US10292482B2 (en) 2017-01-06 2019-05-21 Coloright Ltd. Hair-holder, hair-reader comprising the same, and methods for optically acquiring data from hair

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1912354B2 (de) * 1969-03-12 1972-04-13 Reimbold & Strick, 5000 Köln-Kalk Synthetisches kristallines calciumsilikat und verfahren zu seiner herstellung
FR2234244B1 (es) * 1973-06-20 1978-02-17 Rech Geolog Miniere
DE2556561C2 (de) * 1975-12-16 1983-04-14 Boehringer Mannheim Gmbh, 6800 Mannheim Verfahren zur Herstellung von porösen Tabletten
DE2845326C2 (de) * 1978-10-18 1985-05-23 Beiersdorf Ag, 2000 Hamburg Verwendung einer spezifischen mikrodispersen, amorphen, porösen Kieselsäure zur Herstellung von Digoxin enthaltenden Tabletten mit stark beschleunigter Wirkstoff-Freisetzung
DE2849494A1 (de) * 1978-11-15 1980-05-29 Voss Gunter M Verfahren zur herstellung von arzneimittel-formlingen
US4327080A (en) * 1981-07-13 1982-04-27 E. R. Squibb & Sons, Inc. Novel Bendroflumethiazide formulations and method
KR940000232B1 (ko) * 1986-01-17 1994-01-12 쥬우가이세이야꾸 가부시끼가이샤 니코란딜 제제의 안정화 방법
SE8601624D0 (sv) * 1986-04-11 1986-04-11 Haessle Ab New pharmaceutical preparations
US5032552A (en) * 1988-07-04 1991-07-16 Tdk Corporation Biomedical material
US5006528A (en) * 1988-10-31 1991-04-09 Otsuka Pharmaceutical Co., Ltd. Carbostyril derivatives
HU203041B (en) * 1989-03-14 1991-05-28 Egyt Gyogyszervegyeszeti Gyar Process for producing pharmaceutical compositions of controlled releasing factor containing nifedipin
JPH06271744A (ja) * 1993-03-22 1994-09-27 Mizusawa Ind Chem Ltd ポリアセタール系樹脂用帯電防止剤
US5393472A (en) * 1993-06-30 1995-02-28 Shaw; John D. Method of producing wollastonite & ceramic bodies containing wollastonite
US5622719A (en) * 1993-09-10 1997-04-22 Fuisz Technologies Ltd. Process and apparatus for making rapidly dissolving dosage units and product therefrom
US5895664A (en) * 1993-09-10 1999-04-20 Fuisz Technologies Ltd. Process for forming quickly dispersing comestible unit and product therefrom
US5994348A (en) * 1995-06-07 1999-11-30 Sanofi Pharmaceutical compositions containing irbesartan
AU3865595A (en) * 1995-11-17 1997-06-11 Vrije Universiteit Brussel Inorganic resin compositions, their preparation and use thereof
EP1380308B1 (en) * 1996-07-12 2008-07-09 Daiichi Pharmaceutical Co., Ltd. Quickly disintegrable compression-molded materials and process for producing the same
US6133378A (en) * 1998-11-20 2000-10-17 Bridgestone/Firestone, Inc. EPDM-based roofing shingle compositions
US20020076437A1 (en) * 2000-04-12 2002-06-20 Sanjeev Kothari Flashmelt oral dosage formulation
US6610266B2 (en) * 2001-11-28 2003-08-26 Michael C. Withiam Calcium metasilicates and methods for making

Also Published As

Publication number Publication date
US20070275059A1 (en) 2007-11-29
TWI324074B (en) 2010-05-01
UY27474A1 (es) 2003-05-30
MY127350A (en) 2006-11-30
AR098808A2 (es) 2016-06-15
US20050019398A1 (en) 2005-01-27
AR036658A1 (es) 2004-09-22

Similar Documents

Publication Publication Date Title
PE20030557A1 (es) Formulacion de dosificacion oral de fusion instantanea
CL2009001279A1 (es) Compuestos derivados de nociceptina; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento del dolor (sol. divisional 2103-03).
ES2033426T3 (es) Procedimiento para la preparacion de composiciones farmaceuticas de liberacion controlada que contienen 3'-azido-3'-desoxitimidina.
BR0202278A (pt) Dispositivos e processos para a colheita de células
ATE536173T1 (de) Formulierungen mit modifizierter freisetzung von mindestens einer form von tramadol
BR0004786A (pt) Compostos farmaceuticamente ativos
CR6895A (es) Nuevos compuestos heterociclicos su preparacion y su utilizacion como medicamentos en especial como antibacterianos
BR9905109A (pt) "compostos farmaceuticamente ativos"
BR9907300A (pt) Inibidores do fator xa oxoaza-heterociclila substituìdos
BR0111034A (pt) Composto, composição farmacêutica, uso de um composto, e, métodos para o tratamento ou profilaxia de condições ou doenças inflamatórias, para o tratamento e/ou profilaxia de osteoporose e para o tratamento de doenças relacionadas à aids
HUP0400781A3 (en) Process for the crystallization of (r)- or (s)-lansoprazole, the prepared crystalls and pharmaceutical compositions containing them and their use
BR0016665A (pt) Composição alvejante, e, métodos de alvejamento e de preparação de uma composição alvejante
PT92002A (pt) Processo para a preparacao de formulacoes dispensaveis que contem diclofenac
PE118999A1 (es) Composiciones y metodos para tratar trastornos respiratorios
BR0209283A (pt) Método para a fabricação de uma composição farmacêutica de baixa dosagem tendo distribuição e potência de droga uniforme
PA8426801A1 (es) Composiciones farmaceuticas para el tratamiento de la rinitis.
EA200401397A1 (ru) Композиции-ингибиторы циклооксигеназы-2, содержащие 2-(3,5-дифторфенил)-3-[4-(метилсульфонил)фенил]-2-циклопентен-1-он или (s)-6,8-дихлор-2-(трифторметил)-2h-1-бензопиран-3-карбоновую кислоту
AU2002343661A1 (en) Modified prostaglandin compounds and analogs thereof, compositions containing the same useful for the teatment of cancer
BR0210266A (pt) Composição farmacêutica que compreende um inibidor de lìpases, processo para preparar essa composição, conjunto para o tratamento de obesidade, utilização da composição, processo de tratamento de obesidade e inibidor de lìpases
ATE440838T1 (de) Pharmazeutisch aktive sulfonylaminosäurederivate
AR021845A1 (es) Derivados de 1,3-diaril-2-piridin-2-il-3-(piridin-2-ilamino)-propanol sustituidos, composiciones farmaceuticas y medicamentos que las comprenden, procedimientos para su preparacion, medicamentos que contienen estos compuestos, y su utilizacion para la preparcion de medicamentos
BR0008382A (pt) Formulação de liberação controlada para tratamento de copd
MXPA03008801A (es) Aril oxima-piperazinas utiles como antagonistas de ccr5.
YU37001A (sh) Kombinacija lekova analgetika
BR9804386A (pt) Método para a redistribuição de policarbonato com a decomposição de catalisador

Legal Events

Date Code Title Description
FC Refusal